HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Lumos Pharma, maintaining a price target of $28. This suggests confidence in the company's future performance.
September 27, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Lumos Pharma, maintaining a price target of $28. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $28 price target by HC Wainwright & Co. indicates a positive outlook for Lumos Pharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100